JP2010515750A5 - - Google Patents

Download PDF

Info

Publication number
JP2010515750A5
JP2010515750A5 JP2009545669A JP2009545669A JP2010515750A5 JP 2010515750 A5 JP2010515750 A5 JP 2010515750A5 JP 2009545669 A JP2009545669 A JP 2009545669A JP 2009545669 A JP2009545669 A JP 2009545669A JP 2010515750 A5 JP2010515750 A5 JP 2010515750A5
Authority
JP
Japan
Prior art keywords
group
carbon atoms
groups
nitrogen
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2009545669A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010515750A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/050695 external-priority patent/WO2008089015A1/en
Publication of JP2010515750A publication Critical patent/JP2010515750A/ja
Publication of JP2010515750A5 publication Critical patent/JP2010515750A5/ja
Abandoned legal-status Critical Current

Links

JP2009545669A 2007-01-11 2008-01-10 スフィンゴシン−1−ホスフェート(s1p)受容体アンタゴニスト生物活性を有する6−置換インドール−3−カルボン酸アミド化合物 Abandoned JP2010515750A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88447007P 2007-01-11 2007-01-11
PCT/US2008/050695 WO2008089015A1 (en) 2007-01-11 2008-01-10 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity

Publications (2)

Publication Number Publication Date
JP2010515750A JP2010515750A (ja) 2010-05-13
JP2010515750A5 true JP2010515750A5 (enExample) 2011-03-03

Family

ID=39399972

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009545669A Abandoned JP2010515750A (ja) 2007-01-11 2008-01-10 スフィンゴシン−1−ホスフェート(s1p)受容体アンタゴニスト生物活性を有する6−置換インドール−3−カルボン酸アミド化合物

Country Status (8)

Country Link
EP (1) EP2125723A1 (enExample)
JP (1) JP2010515750A (enExample)
KR (1) KR20090101307A (enExample)
CN (1) CN101668741A (enExample)
AU (1) AU2008206495A1 (enExample)
CA (1) CA2674946A1 (enExample)
MX (1) MX2009007334A (enExample)
WO (1) WO2008089015A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524917B2 (en) 2007-01-11 2013-09-03 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
CA2718705A1 (en) * 2008-03-17 2009-09-24 Allergan, Inc. S1p3 receptor inhibitors for treating inflammation
KR20190004843A (ko) 2008-07-23 2019-01-14 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[b]인돌-3-일)아세트산 유도체
JP5726737B2 (ja) 2008-08-27 2015-06-03 アリーナ ファーマシューティカルズ, インコーポレイテッド 自己免疫障害および免疫性障害の治療において有用なs1p1受容体のアゴニストとしての置換三環式酸誘導体
CN108558740B (zh) 2010-01-27 2021-10-19 艾尼纳制药公司 S1p1受体调节剂及其盐的制备方法
CA2789480A1 (en) 2010-03-03 2011-09-09 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
TWI522361B (zh) * 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
CN112500338A (zh) 2013-03-15 2021-03-16 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
HUE060476T2 (hu) 2015-06-22 2023-03-28 Arena Pharm Inc (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CN110545848A (zh) 2017-02-16 2019-12-06 艾尼纳制药公司 用于治疗具有肠外表现的炎症性肠病的化合物和方法
CN110483437B (zh) * 2018-05-14 2022-12-06 嘉兴维眸生物科技有限公司 一种含五元环的化合物及其制备和应用
US12156866B2 (en) 2018-06-06 2024-12-03 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
EP3847158A1 (en) 2018-09-06 2021-07-14 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2121394A1 (fr) * 1971-01-08 1972-08-25 Anvar Procédé d'obtention de dérivés d'acides indole carboxyliques et produits préparables par ce procédé.
EP0146810A3 (de) 1983-12-05 1987-05-13 Solco Basel AG Verfahren zur Herstellung von Sphingosinderivaten
US5110987A (en) 1988-06-17 1992-05-05 Emory University Method of preparing sphingosine derivatives
NZ233285A (en) 1989-04-18 1992-06-25 Duphar Int Res Imidazole-substituted carbamoyl-indoles and condensed analogues thereof and pharmaceutical compositions
US5294722A (en) 1992-04-16 1994-03-15 E. R. Squibb & Sons, Inc. Process for the preparation of imidazoles useful in angiotensin II antagonism
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
KR19990076788A (ko) 1996-01-22 1999-10-15 후지야마 아키라 티아졸릴벤조푸란 유도체 및 그를 함유하는 약제학적 조성물
WO1998040349A1 (en) 1997-03-12 1998-09-17 Takara Shuzo Co., Ltd. Sphingosine analogues
KR100561890B1 (ko) 1997-09-11 2006-03-16 다카라 바이오 가부시키가이샤 스핑고신류 유도체 및 의약 조성물
DE19753522A1 (de) 1997-12-03 1999-06-10 Boehringer Ingelheim Pharma Substituierte Indole, ihre Herstellung und ihre Verwendung als Arzneimittel
AP2001002228A0 (en) * 1999-01-13 2001-09-30 Millenium Pharmaceuticals Inc Functionalized heterocycles as chemokine receptor modulators.
WO2001098301A1 (en) 2000-06-20 2001-12-27 Japan Tobacco Inc. Pyrazolopyridine compounds and use thereof as drugs
DK1397130T3 (da) 2001-06-20 2007-11-12 Wyeth Corp Substituerede indolsyrederivater som inhibitorer af plasminogenaktivatorinhibitor-1 (PAI-1)
WO2003070691A1 (en) * 2002-02-21 2003-08-28 Osaka Industrial Promotion Organization N-hydroxycarboxamide derivative
EP1984334B1 (en) 2006-02-15 2014-04-09 Allergan, Inc. Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity

Similar Documents

Publication Publication Date Title
JP2010515750A5 (enExample)
RU2009102535A (ru) Производные карбамидов тропана, их получение и их применение в терапии
JP2018509418A5 (enExample)
CA2565813A1 (en) Substituted methyl aryl or heteroaryl amide compounds
PE20110852A1 (es) Antagonistas del receptor de orexina de isonicotinamida
RU2007146798A (ru) ПРОИЗВОДНЫЕ 4-(2-АМИНО-1-ГИДРОКСИЭТИЛ)ФЕНОЛА КАК АГОНИСТЫ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА
RU2009115963A (ru) Производные оксадиазола, обладающие противовоспалительными и иммунодепрессантными свойствами
JP2013518129A5 (enExample)
RU2008152180A (ru) ПРОИЗВОДНЫЕ ПИРРОЛА, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ CRTh2 РЕЦЕПТОРА
JP2011519374A5 (enExample)
RU2009148336A (ru) Гетероциклические соединения в качестве положительных модуляторов метаботропного глутаматного рецептора 2 (рецептора mglu2)
JP2011515398A5 (enExample)
KR101360556B9 (ko) 글리코피롤레이트 및 베타2 아드레날린 수용체아고니스트의 조합물
CY1109493T1 (el) Παραγωγα οξαζολιου ως παραγοντες η3 υποδοχεα ισταμινης, παρασκευη και θεραπευτικες χρησεις
IL185844A0 (en) I-acetic acid-indole derivatives with pgd2 antagonist activity
TN2009000084A1 (en) Adenosine derivatives as a2a receptor agonists
JP2011515483A5 (enExample)
JP2012513990A5 (enExample)
MX2009009492A (es) Compuestos organicos biciclicos adecuados para el tratamiento de condiciones inflamatorias o alergicas.
RU2014122035A (ru) Соединения с нематоцидной активностью
AR062299A1 (es) Derivados de bencimidazol
ATE388146T1 (de) 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor
TW200734322A (en) Indole derivatives exhibiting PGD2 receptor antagonism
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
PE20120655A1 (es) Derivados de triazolopiridina como inhibidores de proteinas cinasas activadas por mitogeno p38 (map)